NASDAQ:NUWE - Nasdaq - US67113Y6032 - Common Stock - Currency: USD
NUWELLIS INC
NASDAQ:NUWE (1/29/2025, 2:33:21 PM)
1.11
-0.05 (-4.31%)
The current stock price of NUWE is 1.11 USD. In the past month the price increased by 1.31%. In the past year, price decreased by -93.1%.
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people...
The FDA and Nuwellis warn of potential risks linked to AquaFlexFlow UF 500 Plus blood circuits. A recall addresses issues like therapy termination and patient injury risks.
MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received...
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with...
MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.45 | 222.38B | ||
ISRG | INTUITIVE SURGICAL INC | 78.39 | 204.65B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.49 | 151.26B | ||
SYK | STRYKER CORP | 32.16 | 149.47B | ||
MDT | MEDTRONIC PLC | 17.52 | 117.93B | ||
BDX | BECTON DICKINSON AND CO | 18.78 | 71.66B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.82 | 42.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.81 | 40.12B | ||
RMD | RESMED INC | 30.24 | 36.81B | ||
IDXX | IDEXX LABORATORIES INC | 37.74 | 33.83B | ||
DXCM | DEXCOM INC | 50.68 | 33.65B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.41 | 25.71B |
Nuwellis Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eden Prairie, Minnesota and currently employs 59 full-time employees. The company went IPO on 2012-02-16. Nuwellis, Inc. is a medical technology company. The firm is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
NUWELLIS INC
12988 Valley View Rd
Eden Prairie MINNESOTA 55344 US
CEO: Nestor Jaramillo
Employees: 59
Company Website: https://www.nuwellis.com/
Investor Relations: http://ir.sunshineheart.com/
Phone: 19523454200
The current stock price of NUWE is 1.11 USD.
The exchange symbol of NUWELLIS INC is NUWE and it is listed on the Nasdaq exchange.
NUWE stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NUWE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NUWE.
NUWE does not pay a dividend.
NUWE does not have a PE ratio as the earnings reported over the last twelve months were negative (-92.71).
The outstanding short interest for NUWE is 7.78% of its float.
ChartMill assigns a technical rating of 1 / 10 to NUWE. When comparing the yearly performance of all stocks, NUWE is a bad performer in the overall market: 96.65% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NUWE. The financial health of NUWE is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NUWE reported a non-GAAP Earnings per Share(EPS) of -92.71. The EPS increased by 83.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -253.91% | ||
ROE | -537.37% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to NUWE. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 94.66% and a revenue growth 0.2% for NUWE